GS-626510 disrupts the function of proteins that recognize and bind specific epigenetic marks, affecting the interpretation of epigenetic signals. It targets BD1, BD2, BRD2, BRD3, and BRD4.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.